US 12,338,458 B2
Use of the IL-15/IL-15Rα complex in the generation of antigen-specific T cells for adoptive immunotherapy
Richard John O'Reilly, Roxbury, CT (US); Bo Dupont, Harrison, NY (US); Aisha Nasreen Hasan, Blue Bell, PA (US); Annamalai Selvakumar, West Orange, NJ (US); and Xiao-Rong Liu, Astoria, NY (US)
Assigned to Memorial Sloan Kettering Cancer Center, New York, NY (US)
Appl. No. 16/616,099
Filed by Memorial Sloan Kettering Cancer Center, New York, NY (US)
PCT Filed May 25, 2017, PCT No. PCT/US2017/034364
§ 371(c)(1), (2) Date Nov. 22, 2019,
PCT Pub. No. WO2018/217203, PCT Pub. Date Nov. 29, 2018.
Prior Publication US 2020/0157502 A1, May 21, 2020
Int. Cl. C12N 5/0783 (2010.01); A61K 40/10 (2025.01); A61K 40/11 (2025.01); A61K 40/24 (2025.01); A61K 40/46 (2025.01); C07K 14/725 (2006.01)
CPC C12N 5/0636 (2013.01) [A61K 40/10 (2025.01); A61K 40/11 (2025.01); A61K 40/24 (2025.01); A61K 40/46 (2025.01); C07K 14/7051 (2013.01); C12N 5/0638 (2013.01); C12N 2501/2315 (2013.01); C12N 2502/11 (2013.01)] 27 Claims
 
1. A method of generating an expanded population of cells comprising antigen-specific CD62L+central memory T cells for therapeutic administration to a human patient having or suspected of having a pathogen or cancer, comprising ex vivo culturing a population of human blood cells comprising human antigen-specific T cells over a period of time in culture in the presence of soluble IL-15/IL-15Rα complexes while in the absence of cells recombinantly expressing soluble IL-15/IL-15Rα complexes,
wherein the human antigen-specific T cells are specific to one or more antigens of the pathogen or cancer, and wherein the IL-15Rα subunit in the soluble IL-15/IL-15Rα complexes in the culture present with the population of human blood cells is a fragment of wild-type human IL-15Rα that retains the ability to bind to IL-15 but lacks the ability to be anchored to the cell membrane by itself, and
wherein the IL-15 subunit and the IL-15Rα subunit are in a 1:1 molar ratio.